Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies.
Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez JF, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gúrpide J, Lluch A, Bermejo B, Sancenón F, Cejalvo JM, Martínez-Máñez R, Eroles P. Garrido-Cano I, et al. Among authors: zazo s. Cancer Commun (Lond). 2022 Dec;42(12):1412-1416. doi: 10.1002/cac2.12352. Epub 2022 Aug 23. Cancer Commun (Lond). 2022. PMID: 35997029 Free PMC article. No abstract available.
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J. Rojo F, et al. Among authors: zazo s. Ann Oncol. 2012 May;23(5):1156-1164. doi: 10.1093/annonc/mdr361. Epub 2011 Sep 9. Ann Oncol. 2012. PMID: 21908496 Free article.
PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I, Manso R, Rincón R, Caramés C, Senin C, Borrero A, Martínez-Useros J, Rodriguez M, Zazo S, Aguilera O, Madoz-Gúrpide J, Rojo F, García-Foncillas J. Cristóbal I, et al. Among authors: zazo s. Mol Cancer Ther. 2014 Apr;13(4):938-47. doi: 10.1158/1535-7163.MCT-13-0150. Epub 2014 Jan 21. Mol Cancer Ther. 2014. PMID: 24448818
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
del Puerto-Nevado L, Rojo F, Zazo S, Caramés C, Rubio G, Vega R, Chamizo C, Casado V, Martínez-Useros J, Rincón R, Rodríguez-Remírez M, Borrero-Palacios A, Cristóbal I, Madoz-Gúrpide J, Aguilera O, García-Foncillas J. del Puerto-Nevado L, et al. Among authors: zazo s. Br J Cancer. 2014 May 27;110(11):2700-7. doi: 10.1038/bjc.2014.225. Epub 2014 May 1. Br J Cancer. 2014. PMID: 24786599 Free PMC article.
Clinical significance of miR-126 in colorectal cancer.
Cristóbal I, Aguilera O, García-Foncillas J, Zazo S, Madoz-Gúrpide J, Rojo F. Cristóbal I, et al. Among authors: zazo s. Genes Chromosomes Cancer. 2014 Oct;53(10):881. doi: 10.1002/gcc.22192. Epub 2014 Jun 4. Genes Chromosomes Cancer. 2014. PMID: 24898922 No abstract available.
Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J. García-Parra J, et al. Among authors: zazo s. Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12. Eur J Cancer. 2014. PMID: 25128455
DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J, Rodriguez-Remirez M, Borrero-Palacios A, Moreno I, Cebrian A, Gomez del Pulgar T, del Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, Zazo S, Senin C, Fernandez-Aceñero MJ, Soengas MS, Rojo F, Garcia-Foncillas J. Martinez-Useros J, et al. Among authors: zazo s. BMC Cancer. 2014 Dec 16;14:965. doi: 10.1186/1471-2407-14-965. BMC Cancer. 2014. PMID: 25515240 Free PMC article.
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
Rincón R, Cristóbal I, Zazo S, Arpí O, Menéndez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, Madoz-Gúrpide J, Rojo F. Rincón R, et al. Among authors: zazo s. Oncotarget. 2015 Feb 28;6(6):4299-314. doi: 10.18632/oncotarget.3012. Oncotarget. 2015. PMID: 25726524 Free PMC article.
86 results